Nexign Completed Migration of Subscribers in All Yota’s Branch Offices
Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, today announced the successful migration of subscribers in all branch offices of the Russian mobile broadband services provider Yota to the Nexign Network Monetisation Suite – a versatile solution for real-time rating, charging and policy control across all network services.
Yota was the first operator to offer its customers communication bundles configurable to minutes and gigabytes, as well as differentiated payment for various types of traffic. Yota’s existing solution did not enable horizontal scaling. The company needed a scalable and flexible instrument for charging and policy control inside the network.
To increase effectiveness of its internal processes, Yota opted for Nexign Network Monetisation Suite, which included solutions like PCRF (Policy and Charging Rules Function), RCAF (RAN congestion awareness function) and UDR (User Data Repository).
As a result, Yota received future-proof solution, which fully met the needs of the mobile operator. Yota reduced the total cost of ownership (TCO) by 10-20% by saving on additional third-party licenses. Use of PCRF function enabled the company to reduce time to market (TTM) by 20% and increase the fault tolerance by 40%, which allows the operator to deliver great customer service and stand out from competition. Nexign’s solution helps Yota provide customer services even in the conditions of congestion.
“The jointed project with Nexign allowed us to launch unique product for the telco market called 'The communications constructor' and maintain high quality of our services while increasing the number of customers. In the past six months the new solution underwent unprecedented stress test. Due to the pandemic, traffic from business apps inside the network has grown 2.5 times,” said Andrey Zhikin, IT Director of Yota.
“This project is the first time when Nexign implemented its solution in a telecom operator that uses a third-party billing system,” said Alexey Vedin, Director of Network Monetisation Products at Nexign. “Integration with Yota’s BSS systems was carried out with no impact on Yota’s customers and without any failures or service interruption. No additional modifications were required on the part of billing or other systems – all the needs of the operator were covered by the capabilities of Nexign’s solution.”
Learn more about Nexign’s products and services here: https://nexign.com/en.
About Nexign
Nexign, a part of Intellectual Computer Systems Holding (https://x-holding.ru/) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering pragmatic, value-driven, high-performance product solutions since 1992. Nexign has an experience of transformational projects of all scales, and a proven track record of achieving revenue boosts for CSPs through systems consolidation and a faster go-to-market time for new services after modernisation.
Headquartered in St. Petersburg, Nexign employs 1,800 people in offices through Russia, the CIS, the Middle East, Africa, Southeast Asia and LATAM. For more information, please visit the website and follow Nexign on Twitter, Facebook and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006022/en/
Contact information
Alena Semenova
Alena.Semenova@nexign.com
+79117237518
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 15:30:00 EET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling anti-tumor activity for ADVC001 in patients with mCRPC (see press release). ADVC001 is a first-in-class 212Pb-PSMA RLT in clinical development, with early data indicating a differentiated and competitive profile both within and beyond its class. Development is advancing rapidly; the Phase 1b therapeutic cohorts were enrolled within ten months, and the commencement of Phase 2 expansion sustains this strong program momentum. The TheraPb Phase 2 expansion will evaluate ADVC001 at two therapeutic dose levels – 160 MB
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 15:00:00 EET | Press release
Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING NEW LONDON OFFICE As creative economies decentralize and new production hubs emerge across EMEA, Luma AI is positioning its capabilities where creative work is increasingly being produced - not just consumed. To build intelligence that truly serves global creators, Luma AI will work alongside them in their markets, cultures, and workflows. London is the first step in that strategy, as it has the unique position as a global center of advertising, brands, and entertainment. “With this Series C raise and the upcoming build-out
Aurigene Oncology Limited Announces Encouraging Initial Data From 1 st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 15:00:00 EET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 14:30:00 EET | Press release
Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after closing the transaction. These include building a dedicated m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom